Eli Lilly wins a quick OK for new sarcoma drug olaratumab
Eli Lilly has won an accelerated FDA approval of its soft tissue sarcoma drug olaratumab with set of positive results from a small mid-stage study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
